Innovent Biologics Announces Major Regulatory Win: Jaypirca® (Pirtobrutinib) Approved in China for Relapsed or Refractory CLL/SLL

Innovent Biologics, Inc. (HKEX: 1801) has delivered a significant update that could have a material impact on its business and share price. The company announced that Jaypirca® (pirtobrutinib), a novel non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, has received regulatory approval from the National Medical Products Administration (NMPA) of China for a new indication in the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received at least one line of systemic therapy, including a BTK inhibitor.

Key Points of the Announcement

• Major Regulatory Approval: Jaypirca’s new indication in China for CLL/SLL follows earlier FDA approval in the U.S. and marks an expansion of Innovent’s oncology portfolio in one of the world’s largest healthcare markets.
• First-in-Class Mechanism: Jaypirca is a highly selective, non-covalent (reversible) BTK inhibitor, offering a new treatment option for patients who have previously failed covalent BTK inhibitor therapies (ibrutinib, acalabrutinib, or zanubrutinib).
• Robust Clinical Data: Approval is based on the international, multicenter, randomized Phase 3 BRUIN CLL-321 study—the first of its kind globally in this patient population. The study enrolled 238 patients and demonstrated that Jaypirca significantly prolonged median progression-free survival (PFS) to 14.0 months compared to 8.7 months for standard-of-care regimens (HR = 0.54).
• Improved Safety Profile: The rate of discontinuation due to treatment-related adverse events was notably lower for Jaypirca (5.2%) than for comparator therapies (21.1%), highlighting its tolerability.
• Commercial Implications: The approval positions Innovent to leverage its strong brand and commercial capabilities in oncology to accelerate patient access to Jaypirca across China.

Details Investors Should Note

• Market Expansion: This approval marks Jaypirca’s entry into a significant new market segment. Previously, the drug was approved in China only for relapsed/refractory mantle cell lymphoma (MCL).
• First-Mover Advantage: Jaypirca is the first non-covalent BTK inhibitor approved for CLL/SLL patients previously treated with covalent BTK inhibitors, potentially establishing Innovent as a market leader in this therapeutic area.
• Unmet Medical Need: CLL/SLL represents 6-7% of non-Hodgkin lymphoma cases in China. There is a substantial patient population that may benefit from this therapy, especially after failure of standard BTK inhibitors.
• Clinical Differentiation: Jaypirca’s mechanism (300x more selective for BTK than 98% of other kinases tested in preclinical studies) and safety profile differentiate it from existing therapies.
• Strategic Collaboration: Jaypirca was developed by Eli Lilly and Company and is commercialized in mainland China by Innovent, reflecting continued partnership and alignment with a global pharmaceutical leader.
• Potential Impact on Share Price: This regulatory milestone could drive significant revenue growth for Innovent and is likely to be viewed positively by investors given the size of the addressable market, the first-mover status, and strong supporting clinical data.

Supporting Clinical Data

The BRUIN CLL-321 study, a randomized, open-label Phase 3 trial, compared Jaypirca to investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory CLL/SLL after prior treatment with a covalent BTK inhibitor. Primary endpoint was PFS as assessed by a blinded independent review committee. Secondary endpoints included overall response rate, duration of response, event-free survival, overall survival, time to next treatment, safety/tolerability, and patient-reported outcomes. Jaypirca outperformed comparators across key efficacy and safety endpoints.

About Jaypirca (Pirtobrutinib)

Jaypirca is a highly selective, non-covalent inhibitor of BTK, a validated molecular target in multiple B-cell malignancies. Its differentiated mechanism allows it to retain activity in patients with resistance to covalent BTK inhibitors, offering new hope for patients with relapsed or refractory disease.

About CLL/SLL in China

CLL and SLL are slow-growing forms of non-Hodgkin lymphoma originating from lymphocytes. In China, CLL represents about 6-7% of non-Hodgkin lymphoma cases. SLL is pathologically and immunophenotypically identical to CLL, differing mainly in the location of cancer cells (blood for CLL, lymph nodes for SLL).

Company Statement

Innovent Biologics stated that this approval is a significant breakthrough for CLL/SLL patients in China, ensuring timely access to a global innovation in therapy. The company intends to fully leverage its brand and commercialization infrastructure to maximize patient access and market penetration.

Corporate Governance

As of the announcement date, the Board of Innovent Biologics is chaired by Dr. De-Chao Michael Yu, with a mix of executive and independent non-executive directors providing oversight.

Investor Takeaway

This regulatory approval is highly significant and likely to be price sensitive. It expands Innovent’s addressable market, establishes a unique therapeutic offering, and may drive substantial revenue growth. The robust clinical data, improved safety profile, and strategic collaborations further strengthen Innovent’s leadership in oncology therapeutics in China.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professional advisers before making investment decisions. The author and publisher are not responsible for any losses arising from reliance on this information.

View INNOVENT BIO Historical chart here